{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:03Z","timestamp":1790842083995,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T00:00:00Z","timestamp":1586044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GSP 13002"],"award-info":[{"award-number":["GSP 13002"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The advent of new therapies in spinal muscular atrophy (SMA) has highlighted the need to have natural history data for comparison. Natural history studies using structured assessments in type I however are very limited. We identified and reviewed all the existing longitudinal history data in infants with type I SMA first assessed before the age of 7\u2009months with the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main text<\/jats:title>\n                    <jats:p>\n                      Three longitudinal natural history studies, two performed in the United States and one in Italy, were identified. The different study design of these three studies made it possible for the cumulative dataset to include the full spectrum of severity; from infants with neonatal onset to those with a milder phenotype that were not always included in the individual natural history studies. The cumulative analysis confirmed that, even in a larger cohort, there was never an improvement on the CHOP INTEND over time. This was true for all the infants, irrespective of their age or baseline CHOP INTEND scores. Infants with neonatal onset had low CHOP INTEND scores and a fast decline. The relatively large number of patients allowed us to calculate the rate of progression in subgroups identified according to\n                      <jats:italic>SMN2<\/jats:italic>\n                      copy number and baseline CHOP INTEND scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A detailed understanding of the existing data is important, as it will be difficult to acquire new systematic longitudinal history data because of the availability of disease modifying therapies. The cumulative findings in this review help to better understand the variability of natural history data in untreated patients and will be of use for comparison to the real world patients treated with the recently approved therapies that have shown encouraging results in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01356-1","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T17:02:41Z","timestamp":1586106161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Longitudinal natural history of type I spinal muscular atrophy: a critical review"],"prefix":"10.1186","volume":"15","author":[{"given":"Eugenio","family":"Mercuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lucibello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Perulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Coratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"de Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Pera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C.","family":"de Vivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,5]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/PHM.0b013e31804b1d66","volume":"86","author":"JR Bach","year":"2007","unstructured":"Bach JR. Medical considerations of long-term survival of Werdnig-Hoffmann disease. Am J Phys Med Rehabil. 2007;86:349\u201355.","journal-title":"Am J Phys Med Rehabil"},{"key":"1356_CR2","first-page":"19","volume":"40","author":"J Borkowska","year":"2002","unstructured":"Borkowska J, Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Zerres K. Early infantile form of spinal muscular atrophy (Werdnig-Hoffmann disease) with prolonged survival. Folia Neuropathol. 2002;40:19\u201326.","journal-title":"Folia Neuropathol"},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1542\/peds.2004-0668","volume":"114","author":"BH Chung","year":"2004","unstructured":"Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004;114:e548\u201353.","journal-title":"Pediatrics"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810\u20137.","journal-title":"Neurology"},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027\u201349.","journal-title":"J Child Neurol"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155\u201361.","journal-title":"Neuromuscul Disord"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O'Hagen JM, McDermott MP, et al. Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26:1499\u2013507.","journal-title":"J Child Neurol"},{"key":"1356_CR8","doi-asserted-by":"publisher","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391. https:\/\/doi.org\/10.1002\/ana.25101. Epub 2017 Dec 8.","DOI":"10.1002\/ana.25101"},{"key":"1356_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","volume":"28","author":"R De Sanctis","year":"2018","unstructured":"De Sanctis R, Pane M, Coratti G, et al. Clinical phenotypes and trajectories of disease progression in type I spinal muscular atrophy. Neuromuscul Disord. 2018;28:24\u20138.","journal-title":"Neuromuscul Disord"},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.283","volume":"3","author":"SJ Kolb","year":"2016","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016;3:132\u201345.","journal-title":"Ann Clin Transl Neurol"},{"key":"1356_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197\u2013207.","journal-title":"Neuromuscul Disord"},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315.","journal-title":"Neuromuscul Disord"},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JND-180301","volume":"5","author":"AM Glanzman","year":"2018","unstructured":"Glanzman AM, Mazzone ES, Young SD, et al. Evaluator training and reliability for SMA global Nusinersen trials. J Neuromuscul Dis. 2018;5:159\u201366.","journal-title":"J Neuromuscul Dis"},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1474-4422(17)30041-8","volume":"16","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Balabanov P, Binetti L, et al. Stakeholder collaboration for spinal muscular atrophy therapy development. Lancet Neurol. 2017;16:264.","journal-title":"Lancet Neurol"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","volume":"91","author":"K Aragon-Gawinska","year":"2018","unstructured":"Aragon-Gawinska K, Seferian AM, Daron A, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type I: a cohort study. Neurology. 2018;91:e1312\u20138.","journal-title":"Neurology"},{"key":"1356_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","volume":"28","author":"M Pane","year":"2018","unstructured":"Pane M, Palermo C, Messina S, et al. Nusinersen in type I SMA infants, children and young adults: preliminary results on motor function. Neuromuscul Disord. 2018;28:582\u20135.","journal-title":"Neuromuscul Disord"},{"key":"1356_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejpn.2017.11.001","volume":"22","author":"A Pechmann","year":"2018","unstructured":"Pechmann A, Langer T, Wider S, Kirschner J. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type I. Eur J Paediatr Neurol. 2018;22:122\u20137.","journal-title":"Eur J Paediatr Neurol"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1356_CR20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN (Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137.","journal-title":"Neurology"},{"key":"1356_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann A, K\u00f6nig K, Bernert G, et al. SMArtCARE - a platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14:18.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01356-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01356-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01356-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T19:06:06Z","timestamp":1617563166000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01356-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01356-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,5]]},"assertion":[{"value":"30 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval to conduct this study was received by the ethical committees of the participating centres.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eugenio Mercuri has received funding as a member of advisory boards for SMA studies for AveXis, Biogen, Ionis Pharmaceuticals, Inc., Novartis, Scholar Rock \u00a0and Roche; principal investigator for ongoing Ionis Pharmaceuticals, Inc.\/Biogen, Avexis and Roche clinical trials; funding from Famiglie SMA Italy, Italian Telethon, Biogen\u00a0and SMA Europe.Dr. Giorgia Coratti received funding from Biogen, Roche, Avexis and Genesis Pharma as speaker in sponsored symposia.Dr. Roberto de Sanctis received funding from Biogen and Avexis as speaker in sponsored symposia.Dr. Maria Carmela Pera received funding from Roche as speaker in sponsored symposia.Dr. Marika Pane received funding as a member of advisory boards from Biogen and Avexis and as speaker in sponsored symposia.Dr. Jacqueline Montes receives support from the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) 1K01HD084690-01A1 and reports serving as a consultant for Ionis pharmaceuticals and Biogen, and serves on advisory boards for Roche Pharmaceuticals and Biogen.Dr. Darryl C. de Vivo has received personal compensation for activities with AveXis, Biogen, Roche, IONIS, Sarepta, Cytokinetics Pharmaceuticals, and the SMA Foundation and has received research support from NIH, DOD, SMA Foundation, and Hope for Children Research Foundation.Dr. Basil T. Darras has been a scientific advisory board consultant for AveXis, Biogen, Cytokinetics, Marathon, PTC, Roche, and Sarepta; advisor for Ionis Pharmaceuticals, Inc.; research support from the National Institutes of Health\/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, and the SMA Foundation; grants from Ionis Pharmaceuticals, Inc., Biogen, Cytokinetics, Fibrogen, PTC, Sarepta, and Summit.Dr. Stephen J. Kolb has been a scientific advisory board consultant for AveXis, Genentech and Biogen.Dr. Richard S. Finkel Richard Finkel has received personal compensation for activities with Ionis Pharmaceuticals, Biogen, AveXis, Capricor, Catabasis, Lilly, Roche, Novartis; and the SMA Foundation, SMA Europe and Cure SMA as a consultant or advisor. Dr. Finkel has received research support from Ionis Pharmaceuticals, Biogen, Lilly, Cytokinetics Sarepta, NIH, MDA, and Summit.Dr. Simona Lucibello, Dr. Marco Perulli have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}